122 related articles for article (PubMed ID: 35108788)
41. 18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
Promteangtrong C; Kunawudhi A; Phadungrerk R; Iamsa-art C; Chotipanich C
J Med Assoc Thai; 2015 Oct; 98(10):1010-8. PubMed ID: 26638593
[TBL] [Abstract][Full Text] [Related]
42. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
43. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
44. The impact of IV contrast enhanced
Gündoğan C; Tatar G; Erkan E; Çakır MS; Forouz A; Toktaş MG; Çermik TF
Hell J Nucl Med; 2021; 24(1):75-82. PubMed ID: 33928269
[TBL] [Abstract][Full Text] [Related]
45. Contribution of FDG PET/CT for the Optimization of the Management of Additional Lesions Detected on Local Staging Breast MRI.
Jalaguier-Coudray A; Delarbre B; Brenot-Rossi I; Houvenaeghel G; Villard-Mahjoub R; Viens P; Thomassin-Naggara I
AJR Am J Roentgenol; 2016 Apr; 206(4):891-900. PubMed ID: 27003055
[TBL] [Abstract][Full Text] [Related]
46. 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors.
García García-Esquinas M; García-Sáenz JA; Arrazola García J; Enrique Fuentes Ferrer M; Furió V; Rodriguez Rey C; Román JM; Carreras Delgado JL
Q J Nucl Med Mol Imaging; 2014 Mar; 58(1):66-73. PubMed ID: 24104854
[TBL] [Abstract][Full Text] [Related]
47. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging.
Caresia Aroztegui AP; García Vicente AM; Alvarez Ruiz S; Delgado Bolton RC; Orcajo Rincon J; Garcia Garzon JR; de Arcocha Torres M; Garcia-Velloso MJ;
Tumour Biol; 2017 Oct; 39(10):1010428317728285. PubMed ID: 29025377
[TBL] [Abstract][Full Text] [Related]
48. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
Barber TW; Duong CP; Leong T; Bressel M; Drummond EG; Hicks RJ
J Nucl Med; 2012 Jun; 53(6):864-71. PubMed ID: 22582047
[TBL] [Abstract][Full Text] [Related]
49. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
Evangelista L; Cervino AR; Ghiotto C; Saibene T; Michieletto S; Fernando B; Orvieto E; Guarneri V; Conte P
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1648-1655. PubMed ID: 26025244
[TBL] [Abstract][Full Text] [Related]
50. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
51. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
52. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
53. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
54. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
55.
Groheux D; Hindié E
Ann Surg Oncol; 2020 May; 27(5):1708-1709. PubMed ID: 31933220
[No Abstract] [Full Text] [Related]
56. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
[TBL] [Abstract][Full Text] [Related]
57. Role of 2-[18F]fluoro-2-deoxyglucose positron emission tomography in preoperative management of solid-type small-sized lung cancer.
Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
Ann Nucl Med; 2013 Jul; 27(6):515-22. PubMed ID: 23504519
[TBL] [Abstract][Full Text] [Related]
58. Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
Romine PE; Martins RG; Eaton KD; Wood DE; Behnia F; Goulart BHL; Mulligan MS; Wallace SG; Kell E; Bauman JE; Patel SA; Vesselle HJ
BMC Cancer; 2019 Jan; 19(1):70. PubMed ID: 30642285
[TBL] [Abstract][Full Text] [Related]
59. Intratumoral heterogeneity in
Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
[TBL] [Abstract][Full Text] [Related]
60. Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.
Gilardi L; De Cicco C; Colleoni M; Cardillo A; Montagna E; Dellapasqua S; Galimberti V; Bagnardi V; Paganelli G
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1834-41. PubMed ID: 20533032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]